Novartis Invests in End-to-End Manufacturing in U.S.
The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.
Global medicines company, Novartis, has revealed plans to significantly invest in North Carolina, expanding its operations with a new flagship manufacturing hub that offers end-to-end manufacturing capabilities. This expansion forms part of the company’s five-year, USD 23 billion investment into its U.S.-based infrastructure that has been designed to enable full end-to-end production of key medicines within the U.S. (1).
“This announcement is a commitment to American innovation and to the patients we serve,” said Vas Narasimhan, CEO of Novartis, in a company press release (1). “By building a full, end-to-end manufacturing presence in North Carolina for our broader portfolio, we are expanding our capacity to deliver medical breakthroughs, securing a more resilient U.S. supply chain, and investing in the local communities that make our mission possible.”
The plans for the North Carolina flagship hub comprise a new site in Durham that incorporates two new facilities dedicated to the manufacture of biologics and sterile packaging; a new site in Morrisville that includes one facility for solid dosage tablet and capsule production and packaging; and an expansion of the scope of the existing Durham facility to support sterile filling of biologics into syringes and vials. The new flagship hub is expected to open in 2027–2028 and should create 700 new jobs at Novartis and over 3,000 indirect jobs by the end of 2030.
“North Carolina continues to lead in advanced pharmaceutical manufacturing, and Novartis’ expansion in the Triangle reflects our state’s talent and innovative spirit,” added Governor Josh Stein, in the press release (1). “This investment will strengthen our state’s economy and ensure life-saving medicines continue to be made right in North Carolina.”
Earlier in November, the company also announced the opening of its new radioligand therapy (RLT) manufacturing facility in Carlsbad, Calif., which also formed part of the company’s wider investment into its U.S. infrastructure (2). This new facility means the company now has three RLT sites in the U.S. and ensures it is ready to meet future demand.
“At Novartis, we tackle the toughest challenges in medicine by doing what’s never been done before for patients,” commented Narasimhan, in a company press release (2). “Radioligand therapy is a breakthrough we’ve unlocked at scale, made possible by reimagining how innovation reaches patients. As the global leader in RLT for more than seven years, we’ve advanced this technology with a deep belief in its power to transform cancer care. The opening of our Carlsbad facility underscores our strong commitment to the US and dedication to bringing this pioneering treatment to patients across the country.”
References
Novartis. Novartis Announces Plans to Build Flagship Manufacturing Hub in North Carolina. Press Release, Nov. 19, 2025.
Novartis. Novartis Opens New Radioligand Therapy Manufacturing Facility in California as Part of $23B US Expansion Plan. Press Release, Nov. 10, 2025.